Epiphany Biosciences to Continue Phase II Shingles Study
Epiphany Biosciences has announced that a Phase IIb dose-ranging study to evaluate the safety, efficacy, and tolerability of the company’s lead compound, valomaciclovir in patients with acute herpes zoster infection, will continue as originally designed following an interim analysis.
In addition to the Phase IIb zoster study, valomaciclovir will also be studied in a separate Phase II clinical trial as a therapy in managing the most severe sequelae of a herpes-zoster infection, post-herpetic neuralgia.
In addition to the studies directed at herpes zoster, valomaciclovir is also being studied in a Phase II trial of acute infectious mononucleosis, a syndrome commonly seen in adolescents and young adults, caused by Epstein-Barr virus, also a member of the herpes virus family.
Brian Murphy, chief medical officer of Epiphany, said: “We look forward to examining the clinical utility of valomaciclovir in multiple conditions associated with herpes viruses and plan to maximize the broad-acting antiviral profile of this drug.”